Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
Shares of several health-related companies, including Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories, experienced declines after a proposed 2027 federal budget revealed significant spending cuts for key health agencies like the Department of Health and Human Services and the National Institutes of Health. While Congress is unlikely to approve the full extent of the cuts, the proposal introduced uncertainty for the sector, causing immediate stock drops. QuidelOrtho, in particular, saw a 6.4% drop, highlighting the market's sensitivity to perceived threats to medical research funding.
[144] Guardant Health, Inc. SEC Filing
Guardant Health, Inc. (GH) has filed a Form 144 with the SEC, indicating proposed sales of common stock. This filing details a future sale of 3,832 shares through Charles Schwab & Co. on April 1, 2026, stemming from a restricted stock lapse. It also discloses two past sales by Terilyn J. Monroe on January 7, 2026, and January 21, 2026, totaling 18,602 shares.
Guardant Health, Inc. $GH is Capricorn Fund Managers Ltd's 6th Largest Position
Capricorn Fund Managers Ltd significantly increased its stake in Guardant Health (GH) by 197.8% in Q4, making it their 6th largest holding. Despite missing EPS estimates, Guardant Health's Q4 revenue beat expectations, leading several analysts to raise their price targets. The stock has a "Moderate Buy" consensus rating, high institutional ownership, but also saw insider selling.
Guardant Health (GH) Valuation After Japan ENHERTU Approval Backed By InfinityAI Real World Evidence
Guardant Health (GH) is in focus after Japan approved ENHERTU for certain HER2 positive cancers, partly supported by Guardant's InfinityAI platform. Despite a 131.22% one-year return, the stock has seen a recent decline, prompting questions about its valuation. While a narrative suggests a 28.2% undervaluation with a fair value of $130.64 due to AI integration and expanded clinical applications, a sales multiple analysis indicates the stock might appear rich compared to the broader healthcare sector.
Guardant Health (GH) CPO gains stock from RSU vesting and tax withholding
Guardant Health's Chief People Officer, Terilyn J. Monroe, received 8,019 shares of common stock on April 1, 2026, due to the vesting of restricted stock units. Subsequently, 4,187 shares were withheld by the company at $91.15 per share to cover tax obligations. After these transactions, Monroe directly holds 24,822 shares of Guardant Health common stock, reflecting routine equity compensation rather than open-market trading.
Guardant Health (GH) CMO nets shares as RSUs vest and taxes withheld
Guardant Health's Chief Medical Officer, Craig Eagle, acquired 11,400 shares of common stock through the vesting of Restricted Stock Units (RSUs) on April 1, 2026. As part of this process, 5,779 shares were withheld by the company to cover tax obligations. Following these transactions, Eagle directly holds 72,001 shares of Guardant Health common stock.
11,213 Guardant Health (GH) RSUs vest; 4,750 shares withheld for tax
Guardant Health's Chief Commercial Officer, Chris Freeman, had 11,213 Restricted Stock Units (RSUs) vest on April 1, 2026. To cover tax obligations, 4,750 shares were withheld by the company at a price of $91.15 per share. Following these transactions, Freeman directly held 60,034 shares of Guardant Health common stock.
Guardant Health (GH) co-CEO reports RSU vesting, tax-share withholdings and over 2.1M shares held
Guardant Health's co-CEO, Helmy Eltoukhy, reported routine equity compensation activity involving Restricted Stock Units (RSUs) that vested on March 31 and April 1, 2026. These transactions resulted in the conversion of tens of thousands of RSUs into common stock, with shares withheld by the company to cover tax obligations. Following these events, Eltoukhy, through a revocable trust, holds over 2.1 million shares of common stock, in addition to directly holding 68,011 restricted stock units.
SWS Partners Has $7.89 Million Holdings in Guardant Health, Inc. $GH
SWS Partners reduced its stake in Guardant Health (NASDAQ:GH) by 18.3% in the fourth quarter, holding 77,209 shares valued at $7.89 million, representing 1.5% of its portfolio. Guardant Health reported Q4 EPS of -$0.50, missing estimates, but revenue increased by 39.4% to $281.3 million. Analysts have a "Moderate Buy" consensus rating with an average target price of $125.95, despite recent insider selling totaling $2.51 million.
Allspring Global Investments Holdings LLC Reduces Stock Holdings in Guardant Health, Inc. $GH
Allspring Global Investments Holdings LLC significantly reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 1.9% in the fourth quarter, selling 12,256 shares and now owning 618,599 shares valued at $62.94 million. Insider transactions also show sales of 23,250 shares totaling $2.51 million in the last 90 days. Despite these reductions, analysts maintain a "Moderate Buy" rating with an average price target of $125.95 for Guardant Health, a precision oncology company.
Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics
Guardant Health's stock saw a significant increase following the approval of a cancer drug by Daiichi Sankyo in Japan, which utilized real-world evidence from Guardant's InfinityAI platform. This event highlights the growing role of AI and real-world data in regulatory decisions for new treatments, despite the historical volatility of Guardant Health's stock. The article also includes extensive information about an antisera industry report for Japan, unrelated to the main news.
Guardant Health (NasdaqGS:GH) Stock Forecast & Analyst Predictions
Guardant Health (NasdaqGS:GH) is forecasted to experience significant growth, with earnings projected to increase by 55.1% and revenue by 20.9% annually. Despite being unprofitable for the next three years, its revenue growth is expected to outpace the US market. Analysts have also recently increased its price target, signaling positive sentiment for the company's future performance.
Director at Guardant Health (GH) acquires 155 shares via RSUs
Guardant Health director Steve E. Krognes acquired 155 shares of Common Stock by exercising Restricted Stock Units. This transaction on March 31, 2026, was a routine equity-compensation event at an exercise price of $0.00 per share. Following this, Krognes' direct holdings in Common Stock increased to 19,208 shares, and he retains 463 Restricted Stock Units.
Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026
Guardant Health Inc. (NASDAQ: GH) (FRA: 5GH) received the Oncology Product Innovation of the Year award at the Healthcare Asia Medtech Awards 2026 for its Shield multi-cancer detection test. The award comes shortly after Guardant launched Shield in Hong Kong, Singapore, and the Philippines, partnering with Manulife to offer the test to insurance customers. The Shield test, a methylation-based blood test, screens for 10 common cancers with high specificity, improving early detection and patient outcomes.
Guardant Health (GH) and Verana Health Announces New Partnership
Guardant Health (NASDAQ:GH) and Verana Health have announced a new partnership to provide biopharmaceutical researchers with access to Guardant's clinicogenomic testing data and Verana's EHR datasets. This collaboration aims to accelerate the development of new therapies and improve patient care by allowing researchers to connect molecular biomarkers with treatment decisions and clinical outcomes. Guardant Health specializes in precision oncology, using data, blood-based tests, and advanced analytics for cancer treatment.
Why Is Guardant Health (GH) Stock Soaring Today
Guardant Health (GH) stock saw a 5.9% increase after the company announced that its InfinityAI platform's real-world evidence contributed to the approval of the cancer drug ENHERTU® in Japan. This development validates Guardant's AI technology in precision oncology. Despite the recent jump, the stock remains volatile and is down 9.2% year-to-date and 21.2% below its 52-week high.
Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors
Guardant Health's real-world data has supported the Japan Pharmaceuticals and Medical Devices Agency's approval of ENHERTU for treating HER2-positive tumors. This approval represents a significant step forward in personalized medicine for these cancer types, leveraging genomic profiling for treatment decisions. The data likely demonstrated the effectiveness or necessity of identifying HER2 status in patients.
The Bull Case For Guardant Health (GH) Could Change Following Japan’s ENHERTU Approval Using Its AI Data
Guardant Health's InfinityAI and Guardant360 platforms helped secure regulatory approval for Daiichi Sankyo’s ENHERTU in Japan, demonstrating the growing role of AI-driven real-world data in oncology drug approvals. While this reinforces the value of Guardant's data assets, the company still faces challenges with cash burn and achieving profitability. The approval, alongside partnerships like Verana Health, solidifies Guardant's position in AI-enabled oncology data but raises execution risks in converting this data into sustainable revenue.
Guardant Health Inc (GH) Trading Down 3.96% on Mar 30
Guardant Health Inc (GH) experienced a 3.96% decline in its stock price on March 30, trading down to $84.61. While Wall Street analysts have an average target price of $129.67, suggesting a potential upside, GuruFocus estimates a different fair value of $67.08, implying a downside from the current price. The stock's trading volume was significantly higher than its average daily volume during this period.
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
Guardant Health's InfinityAI platform provided crucial real-world evidence, alongside clinical trial data, to support the recent approval of ENHERTU® in Japan. This approval, granted by Japan’s Ministry of Health, Labour and Welfare, is for treating HER2-positive metastatic solid cancers refractory to standard treatments. The collaboration with Daiichi Sankyo highlights the increasing importance of real-world data in expanding access to targeted therapies for rare biomarker-defined patient populations.
Guardant Health to present new cancer research while stock trades lower amid strong sell signals
Guardant Health is set to present 28 abstracts at the AACR26 event, showcasing advancements in cancer diagnostics and research, particularly in methylation-based tumor classification and multiomic testing. Despite this upcoming presentation of new cancer research, the company's stock has experienced a 3.96% intraday drop, trading lower amid strong sell signals and sustained bearish momentum. Technical indicators suggest further downside risk, with the stock positioned below key moving averages and momentum signals pointing to continued seller pressure.
Guardant Health Shares Fall as Market Reacts to Conflict, Policy Deadlines | 2026 - News and Statistics
Guardant Health's stock declined in afternoon trading, reflecting broader market unease fueled by international conflict and upcoming policy deadlines. This market sentiment also pushed consumer confidence to a three-month low, and the company's shares are now trading below their year-to-date peak and are worth less than their value five years ago. The article also provides details on a report about the composite laboratory reagents industry in the United States, including market analysis, trade dynamics, and forecasts to 2035.
Why Guardant Health (GH) Stock Is Falling Today
Guardant Health (GH) stock fell 3% today due to escalating uncertainty from the U.S.-Iran conflict and Trump administration policy deadlines, which also caused major indices to drop. This follows a 3.4% dip almost a month ago driven by higher-than-expected wholesale inflation data. Guardant Health's shares are highly volatile and have fallen 16.7% year-to-date, trading significantly below its 52-week high.
Guardant Health wins at Healthcare Asia Medtech Awards 2026
Guardant Health Pte Ltd won the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards 2026 for its ShieldTM Multi-cancer Detection (MCD) test. This blood test screens for 10 types of cancers, demonstrating 99% overall specificity and 74% sensitivity across six aggressive cancers in recent data. The Shield MCD test has also received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
Tempus AI Reinforces Market Position With Collaborations in 2026
Tempus AI (TEM) is strengthening its market position in 2026 through strategic collaborations with pharmaceutical companies, healthcare institutions, and technology innovators. These partnerships aim to improve clinical outcomes and accelerate drug development by leveraging Tempus's AI expertise and proprietary platforms. Notable collaborations include work with Daiichi Sankyo on an ADC program, Median Technologies for lung nodule characterization, Blood Cancer United for a pediatric AML registry, and NYU Langone Health for cancer care transformation.
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia
Guardant Health (GH) is partnering with Manulife to introduce its Shield multi-cancer detection test across Asia. This collaboration aims to provide enhanced cancer screening options in the region, leveraging Manulife's network to expand access to Guardant Health's diagnostic technology. The initiative represents a significant step in making advanced multi-cancer detection more widely available.
Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary?
Guardant Health (GH) experienced a 5.63% intraday surge to $89.245, driven by a new partnership with Manulife, despite technical indicators like the RSI being deeply oversold. While the rally shows short-term bullish momentum and potential for breakout past the 30-day moving average, it faces resistance around the $90 psychological barrier and requires sustained movement above $95 to confirm a trend reversal. Options traders are targeting calls with high leverage and liquidity, signaling aggressive speculative plays on further upside.
Cancer drug researchers gain combined patient and genomics data
Verana Health and Guardant Health have partnered to combine Verana's EHR datasets with Guardant's clinicogenomic testing data, aiming to accelerate oncology drug development and enhance real-world treatment insights. This collaboration expands access to over 95 million patients and more than 30 academic medical centers, providing biopharmaceutical researchers with comprehensive data to understand patient journeys and validate molecular biomarkers. The partnership is expected to streamline drug development, particularly for solid tumors like lung, breast, and colorectal cancers, and aid in the discovery of new biomarker-based therapies.
Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections
Verana Health and Guardant Health are collaborating to build a robust real-world evidence (RWE) data platform to address precision oncology's data challenges. This partnership integrates Guardant's clinicogenomic datasets with COTA's AI-enhanced oncology data, acquired through Verana's merger, to provide comprehensive insights for drug development. The strategy focuses on high-margin, recurring revenue streams from companion diagnostics and expanding into new therapeutic areas like bladder and prostate cancer, with the goal of driving financial growth and addressing the industry's need for high-quality, research-ready datasets.
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data
Verana Health and Guardant Health have partnered to combine their real-world data resources to accelerate precision medicine, particularly in oncology and urology. This collaboration will allow biopharmaceutical researchers to access curated EHR data alongside clinicogenomic testing data, enhancing the understanding of patient journeys and aiding therapy development. The combined data sets will help validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes, aiming to expedite drug development and personalize cancer treatments.
Guardant Health (GH) director’s RSU vesting adds 264 common shares
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units (RSUs) into common shares. This transaction, part of a routine equity compensation event, increased his direct holdings to 4,487 common shares and 8,184 RSUs. The vested RSUs are from an award granted on November 8, 2024, with a vesting schedule of 25% on the one-year anniversary and the remainder monthly over three years.
Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia
Guardant Health (GH) is under scrutiny after announcing a partnership with Manulife to expand its Shield multi-cancer detection blood test in Asia, starting April 2026. Despite recent share price volatility, the company has shown strong long-term momentum with an 84.77% one-year return, yet some models suggest it's significantly undervalued. The article debates whether the market has already factored in future growth, highlighting potential valuation risks from a high P/S ratio compared to the industry.
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia
Guardant Health (GH) has partnered with Manulife to introduce its Shield multi-cancer detection test in Asia. This collaboration aims to provide early cancer detection solutions to a broader population in the region through Manulife's network. The Shield test is designed to detect multiple types of cancer at early stages, potentially improving patient outcomes.
Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view
This article discusses Piper Sandler's maintained bullish outlook on Guardant Health (GH), specifically reinforced by insights from the company's 2026 screening strategy. The analyst firm highlighted a conference presentation that detailed key upcoming milestones and reiterated confidence in Guardant Health's future growth prospects.
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia
Guardant Health (GH) has partnered with Manulife to launch its Shield multi-cancer detection test in Asia. This collaboration aims to make the early cancer detection test accessible to a broader population in the region, leveraging Manulife's network. The Shield test is designed to detect multiple types of cancer from a single blood draw.
Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH)
Musa Tariq, a Director at Guardant Health Inc (GH), sold 348 shares of the company on March 18, 2026, bringing his total ownership to 8,394 shares. Over the past year, Tariq has sold a total of 4,489 shares with no purchases. Guardant Health Inc is considered significantly overvalued with a price-to-GF-Value ratio of 1.68, based on its trading price of $88.09 against a GF Value of $52.52.
Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock
Guardant Health (NASDAQ:GH) Director Musa Tariq sold 348 shares of the company's stock on March 18, 2026, for a total value of $30,655.32. This sale reduced his stake by 3.98% to 8,394 shares. The company's stock traded up 2.1% to $89.08, and despite missing Q4 EPS estimates, revenue increased by 39.4% year-over-year.
Guardant Health (NASDAQ: GH) director sells 348 company shares
Guardant Health director Tariq Musa sold 348 shares of the company's common stock on March 18, 2026, at an average price of $88.09 per share. This open-market transaction was reported via a Form 4 SEC filing. Following the sale, Musa directly holds 8,394 shares of Guardant Health stock.
Guardant Health (GH) director Tariq Musa sells $30,655 in stock
Guardant Health (GH) director Tariq Musa sold 348 shares of common stock for $30,655 on March 18, 2026, bringing his total direct ownership to 8,394 shares. This insider sale occurs as the company's stock trades near $89.08. Separately, Guardant Health recently reported its Q4 2025 results, with several analysts reaffirming or increasing price targets due to strong performance and a positive outlook for commercial expansion and cost management.
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics
Cathie Wood's ARK sold 11,757 shares of Guardant Health (NASDAQ:GH) totaling over $1 million through its ARKG ETF, continuing a trend of reducing its position in the company. Concurrently, ARK purchased 33,864 shares of Arcturus Therapeutics Holdings (NASDAQ:ARCT) for $216,390, indicating a strategic shift towards innovative therapeutics. A smaller sale of Standard Biotools (NASDAQ:LAB) shares also occurred, reflecting ARK's ongoing portfolio reallocation within the biotech sector.
Director at Guardant Health (GH) receives 232 shares via RSUs
Guardant Health director Manuel Hidalgo Medina received 232 common shares through the exercise of restricted stock units (RSUs) on March 17, 2026, as part of his equity compensation. These shares were converted at a price of $0.00 per share, increasing his direct holdings to 1,425 shares. The RSU award originated from a grant on July 17, 2024, with a four-year vesting schedule.
Guardant Health (NASDAQ: GH) Form 144 shows proposed insider sale of shares
Guardant Health (NASDAQ: GH) has filed a Form 144 indicating proposed insider sales of shares. The filing details planned dispositions of Common Stock linked to restricted stock lapses, with events scheduled for January 15, 2026 (250 shares) and February 15, 2026 (98 shares), handled by Charles Schwab & Co., Inc. This notice acts as a procedural disclosure of intent to sell rather than a record of completed transactions.
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership
Guardant Health, Inc. announced the launch of its Shield multi-cancer detection (MCD) test in several Asian markets through a partnership with Manulife. This collaboration will provide eligible Manulife customers in Hong Kong, Singapore, and the Philippines access to the blood-based test, which screens for 10 common cancers, starting in April 2026. The initiative aims to improve early cancer detection and screening participation in a region where cancer remains a leading cause of death.
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026
Guardant Health and its collaborators will present 28 abstracts, including 3 oral sessions, at the AACR Annual Meeting in April 2026. The presentations will showcase advances in methylation-based tumor classification and liquid biopsy technology, highlighting the utility of Guardant360 Tissue and Guardant360 Liquid in tumor typing and therapy selection. Key data includes high accuracy of Guardant360 Tissue in determining tissue of origin and expanded clinical actionability of Guardant360 Liquid, as well as Guardant Reveal's potential to identify new primary malignancies during MRD monitoring.
Blood tests flag new primary cancers and actionable results in AACR data
Guardant Health will present 28 abstracts at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, highlighting advances in its liquid biopsy technology. Key findings include the high accuracy of Guardant360 Tissue in determining cancer origin, the expanded utility of Guardant360 Liquid in identifying actionable findings for breast and colorectal cancer patients, and Guardant Reveal's potential to detect new primary malignancies during minimal residual disease monitoring. These presentations underscore the power of Guardant's blood- and tissue-based tests in addressing critical gaps in cancer care, from diagnosis to treatment selection.
Guardant Health (NASDAQ:GH) CFO Sells $261,120.00 in Stock
Guardant Health (NASDAQ:GH) CFO Michael Brian Bell sold 3,000 shares of the company's stock for $261,120.00 on March 16, 2026, reducing his stake by 6.44%. The company recently missed EPS expectations in its latest earnings report but exceeded revenue estimates. Guardant Health stock traded at $88.75 mid-day, below its 50-day and 200-day simple moving averages, and institutional investors own approximately 92.6% of the outstanding shares.
Guardant Health (NASDAQ: GH) CLO gains stock through RSU vesting
Guardant Health's Chief Legal Officer, John G. Saia, acquired additional common stock through the vesting of performance-based and time-based Restricted Stock Units (RSUs) on March 15, 2026. After the transactions, and accounting for shares withheld for tax obligations, Mr. Saia directly owns 56,903 shares of Guardant Health common stock. The filing details how 4,622 shares were retained by the company at $85.49 per share to cover tax withholdings related to the RSU vesting.
Guardant Health (GH) director acquires 249 shares via RSU vesting
Guardant Health director Tariq Musa converted 249 restricted stock units (RSUs) into common stock on March 15, 2026, as part of a scheduled vesting. This transaction increased his direct holdings to 8,742 common shares, with an additional 2,999 RSUs remaining. The RSUs, granted on March 6, 2023, vest over four years, with 25% vesting on the first anniversary and the rest monthly over the subsequent three years.
Survey Supports Blood Tests for Colorectal Cancer Screening
A new national survey indicates that 92% of adults eligible for colorectal cancer screening believe blood-based tests should be widely accessible and covered by insurance. These tests could significantly increase screening participation, with 77% of respondents stating they would be less likely to delay screening if a blood test were available. The survey highlights that blood tests could serve as a crucial entry point to screening, potentially overcoming common barriers associated with traditional methods like colonoscopies and stool tests.
Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH)
Artisan Small Cap Fund highlighted its new position in Guardant Health, Inc. (NASDAQ: GH) in its Q4 2025 investor letter. Guardant Health specializes in liquid biopsy diagnostics for cancer detection and monitoring. Despite the fund's investment, Insider Monkey suggests that some AI stocks offer greater potential for higher and faster returns than Guardant Health.
